The idea is to design Potential Kinase inhibitors using Pharmacophore search, Docking, Semantic link association prediction, VROCS and fragment based approach to find novel molecules against Kinases.PASS Prediction
There may be members of this community who do not yet have direct experience of developing a new medicine from concept to pharmacy shelf. Be assured, there is a lot more to it than "just" the synthesis of the API. Why not take advantage of a Free ACS Webcast on May 6, 2010 Thurs 2:00-3:00 PM ET
From a Beaker to a Bottle: Overview of the Drug Discovery and Development Process for Small Molecule Therapeutics
I would like to introduce my open-source project at Stanford, GemIdent:
http://www.gemident.com
http://en.wikipedia.org/wiki/GemIdent
GemIdent specializes in color image segmentation using supervised machine learning. For example, you can use it to locate and count cells in microscopic images:
Published by luogbou on 30 September 2007 - 7:03pm
I am a biochemist i have a good background on molecular biology. i would like to joint a research team to complete my PhD thesis.According to my accademic profile, i am able to work on many research areas like genetic diversity of schistosoma, efficacity of praziquantel, vaccine development against schistosoma spp. and so one.
XDR tuberculosis is resistant to the first-line anti-TB drugs and at least 3 out of 6 of the second line anti-TB drugs. It has an estimated 85% mortality rate. Clearly we're talking about a monster.
I am happy to report that my group in collaboration with Scott Franzblau from the Institute for Tuberculosis Research at U. Illinois-Chicago has published our anti-TB work (see attachment). We explored the quaternized promazine derivatives as antitubercular agents, and found that the most potent thus far are 4- and 3-chlorophenyl derivatives of triflupromazine, both nontoxic in vitro against Vero cells. In our unpublished studies, we have also discovered that both of these actives are bacteriocidal against M. tuberculosis and that the 4-chlorobenzyl derivative is as bacteriocidal as rifampin, the most potent clinically prescribed antitubercular drug. So we're quite happy!
You are invited to the first annual QB3-UCSF-CDD developing world disease research community meeting scheduled for March 5th 2007 at the UCSF Mission Bay Campus (details below and attached). The collaborative community includes leading experts on developing world infectious disease research from Stanford, UCSF, UC Berkeley, UCLA, UW, SBRI, St. Jude CRH, U. Penn, Univ. of Sydney, and industry too.
Collaborative Drug Discovery First Annual Community Meeting
Monday, March 5th 2007 1:00-6:00 pm; Auditorium: J. David Gladstone Institute (1st Floor)
Hosted by Gladstone Institute and QB3 at the UCSF, Mission Bay Campus
Two major themes of this event are:
1)Public-Private-Partnerships for Global Health Issues 2)“Open” concepts for Collaborative Drug Discovery
Confirmed Speakers:
Dr. Christopher Lipinski, Pfizer, retired. (Keynote presentation)
Jim McKerrow, Professor, Dept. of Pathology, QB3 - UCSF
Matt Bogyo, Professor, Dept. of Pathology, Stanford Medical School
Andrej Sali, Professor, Dept of Biopharmaceutical Sciences, QB3 - UCSF
Dr. Anang Shelat, St. Jude Children’s Research Hospital
David Roos, Biology Professor, Univ. of Penn tentatively confirmed (Director, Penn Genomics Institute).
I've just joined Synaptic Leap. I'm a medicinal chemist who is involved in synthesis and computational design of NCEs and I'd like to participate in the discussions.
